Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results ...

Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders ...

The village of Massena is seeking grant funds to offset expected costs associated with water treatment plant upgrades but a recent application for a $10 million grant was denied by state ...

Announced increased focus on type 1 diabetes and in vivo CAR T programsRegulatory interactions increase confidence in moving forward with GMP ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to ...

ITAT Pune ruled that the late filing of the Form 10B audit report is not fatal to the charitable trust exemption if filed before assessment completion. The court reversed the disallowance of ...

Most students who applied for South Carolina’s private K-12 tuition aid program this year were either already attending ...

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from ...

Q3 2025 Earnings Call October 28, 2025 2:00 PM EDTCompany ParticipantsAnn Kelly - CFO & TreasurerAndrew Walters - CEO ...